Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Sanofi Genzyme.

Advances In™ Breast Cancer: New Frontiers in the Management of ER+ Disease

Release Date: October 15, 2021
Expiration Date: October 15, 2022

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of estrogen receptor (ER)-positive breast cancer, with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of therapeutic agents, clinical trial data, current and emerging treatment strategies, and management of treatment-related toxicities will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is directed toward oncologists and other health care professionals involved in the treatment and management of ER+ breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:
  • Discuss the rationale for and mechanism of action of new endocrine agents and targeted therapies for patients with hormone receptor-positive breast cancer
  • Assess recent clinical trial data and ongoing clinical trials evaluating current and investigational therapeutic approaches for hormone receptor-positive breast cancer
  • Develop strategies to recognize, manage, and mitigate the impact of treatment-related adverse events that may occur among patients receiving treatment with endocrine and/or targeted agents for hormone receptor-positive breast cancer

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities


Aditya Bardia, MD, MPH
Aditya Bardia, MD, MPH
Director, Breast Cancer Research Program
Associate Professor, Harvard Medical School
Attending Physician, Medical Oncology, Massachusetts General Hospital
Boston, MA

Disclosures: Grant/Research Support (Institutions): Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, Daiichi Pharma/AstraZeneca. Consultant (Institutions): Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics, Taiho, Sanofi, Daiichi Pharma/AstraZeneca, Puma, Biotheranostics, Phillips, Eli Lilly, Foundation Medicine.

Sara A. Hurvitz, MD
Sara A. Hurvitz, MD
Professor of Medicine
Department of Hematology/Oncology UCLA
Santa Monica, CA

Contracted research paid to institution: Ambrx, Amgen, Astra Zeneca, Arvinas, Bayer, CytomX, Daiichi-Sankyo, Dignitana, Genentech/Roche, Gilead, GSK, Immunomedics, Eli Lilly, MacroGenics, Novartis, Pfizer, OBI Pharma, Pieris Pharmaceuticals, Puma Biotechnology, Radius, Sanofi, Seattle Genetics/Seagen, Zymeworks, Phoenix Molecular Designs, Ltd. Preclinical work (grant paid to UCLA): Ambrx, Samumed. National/International PI: Novartis, Daiichi-Sankyo, Seagen, GNE/Roche. Steering committee: Novartis, Lilly, Daiichi-Sankyo/AZ, GNE/Roche, Sanofi. Travel expenses: Lilly (2019). Uncompensated consulting/ad boards: 4D Pharma, Ambrx, Amgen, Artios Pharma, Arvinas, Daiichi Sankyo, Dantari, Genentech/Roche, Immunomedics, MacroGenics, Eli Lilly, Novartis, NKMAX, Pieris Pharmaceuticals, Pyxis Oncology, Seagen, Biotheranostics.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By